Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Income (2016 - 2025)

Historic Net Income for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Net Income rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 11279.92%. This contributed to the annual value of $16.9 million for FY2024, which is 11957.5% up from last year.
  • Per Gyre Therapeutics' latest filing, its Net Income stood at $5.9 million for Q3 2025, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Net Income ranged from a high of $51.6 million in Q2 2022 and a low of -$101.8 million during Q4 2023
  • For the 5-year period, Gyre Therapeutics' Net Income averaged around -$7.5 million, with its median value being $1.6 million (2025).
  • In the last 5 years, Gyre Therapeutics' Net Income plummeted by 45319.52% in 2021 and then skyrocketed by 35909.27% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Net Income (Quarter) stood at -$20.3 million in 2021, then crashed by 41.75% to -$28.8 million in 2022, then crashed by 253.66% to -$101.8 million in 2023, then skyrocketed by 99.57% to -$433000.0 in 2024, then skyrocketed by 1470.9% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $1.6 million for Q2 2025, and $3.7 million during Q1 2025.